SAGE-217 Emerging Drug Insight

“SAGE-217 Market Size, Forecast, and Emerging Insight – 2032” report provides comprehensive insights about SAGE-217 for Major Depressive Disorder and Postpartum Depression in the seven major markets. A detailed picture of the SAGE-217 in the 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2019 –2032 is provided in this report along with a detailed description of the SAGE-217. The report provides insights about SAGE-217 mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the SAGE-217 market forecast analysis  in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies.

SAGE-217 Drug Summary

Zuranolone (SAGE-217/BIIB125) is a novel, highly potent, and selective, next-generation, an oral, positive allosteric modulator optimized for selectivity to synaptic and extrasynaptic GABAA receptors. The binding sites for NASs are distinct from the recognition sites for GABA, benzodiazepines, and barbiturates. The GABA system is the major inhibitory signaling pathway of the brain and central nervous system (CNS) and contributes significantly to regulating CNS function.

SAGE-217 is currently being developed for MDD. It is being evaluated in the LANDSCAPE and NEST clinical trial programs. The two development programs include multiple studies examining the use of zuranolone in several thousand people with a variety of dosing, clinical endpoints, and treatment paradigms. The LANDSCAPE program includes five studies of zuranolone in people with MDD (MDD-201B, MOUNTAIN, SHORELINE, WATERFALL, and CORAL Studies). The NEST program includes two placebo-controlled studies of zuranolone in people with PPD (ROBIN and SKYLARK Studies). Additionally, Shionogi recently completed a Phase II study of zuranolone in Japan in people with MDD.

SAGE-217 Market Forecast Report Scope

The SAGE-217 Market Forecast Report provides insights into:

•  A comprehensive SAGE-217 Product overview including the SAGE-217 description, SAGE-217 mechanism of action, dosage and administration, research and development activities in Major Depressive Disorder (MDD) and Postpartum depression (PPD).
•  Elaborated details on SAGE-217 regulatory milestones and other development activities have been provided in this report.
•  The SAGE-217 Market Forecast Report also highlights the SAGE-217 research and development activities in Major Depressive Disorder (MDD) and Postpartum depression (PPD) across the United States, Europe and Japan.
•  The SAGE-217 Market Forecast Report also covers the patents information with expiry timeline around SAGE-217.
•  The report contains forecasted SAGE-217 Sales for Major Depressive Disorder (MDD) and Postpartum depression (PPD) till 2032.
•  Comprehensive coverage of the late-stage emerging therapies for MDD.
•  The SAGE-217 Market Forecast Report also features the SWOT analysis with analyst views for SAGE-217 in Major Depressive Disorder (MDD) and Postpartum depression (PPD).

SAGE-217 Methodology

The SAGE-217 Market Forecast Report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

SAGE-217 Market Analytical Perspective by DelveInsight 

• In-depth SAGE-217 Market Assessment

This SAGE-217 Market Report provides a detailed market assessment of SAGE-217 for Major Depressive Disorder (MDD) and Postpartum depression (PPD) in the seven major markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted SAGE-217 Sales data from 2023 to 2032.

•  SAGE-217 Clinical Trials Assessment

The report provides the SAGE-217 Clinical Trials information for Major Depressive Disorder (MDD) and Postpartum depression (PPD) covering trial interventions, trial conditions, trial status, start and completion dates.

SAGE-217 Market Forecast Report Highlights 

•  In the coming years, the SAGE-217 Market scenario for Major Depressive Disorder (MDD) and Postpartum depression (PPD) is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug SAGE-217 Manufacturers to penetrate more into the market.  
•  The SAGE-217 Companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence SAGE-217 dominance.
•  Other emerging SAGE-217 Products for Major Depressive Disorder (MDD) and Postpartum depression (PPD) are expected to give tough market competition to SAGE-217 and launch of late-stage emerging therapies in the near future will significantly impact the SAGE-217 Drug Market.
•  A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of SAGE-217 in Major Depressive Disorder (MDD) and Postpartum depression (PPD).
•  Our in-depth analysis of the forecasted SAGE-217 Sales Data from 2023 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the SAGE-217 in Major Depressive Disorder (MDD) and Postpartum depression (PPD).
• Analyze SAGE-217 Cost, pricing trends, and market positioning to support strategic decision-making in the SAGE-217 Market Landscape.

Key Questions

•  What is the SAGE-217 Product type, route of administration, and SAGE-217 Mechanism of Action?
•  What is the SAGE-217 Clinical Trials status of the study related to SAGE-217 in Major Depressive Disorder (MDD) and Postpartum depression (PPD) and study completion date?
•  What are the key collaborations, mergers and acquisitions, licensing and other activities related to the SAGE-217 development?
•  What are the key designations that have been granted to SAGE-217 for Major Depressive Disorder (MDD) and Postpartum depression (PPD)?
•  What is the forecasted SAGE-217 Market scenario for Major Depressive Disorder (MDD) and Postpartum depression (PPD)?
•  What are the forecasted SAGE-217 Sales in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan? 
•  What are the other emerging SAGE-217 Products available and how are these giving competition to SAGE-217 for Major Depressive Disorder (MDD) and Postpartum depression (PPD)?
•  Which are the late-stage emerging therapies under development for the treatment of Major Depressive Disorder (MDD) and Postpartum depression (PPD)?

Stay updated with us for Recent Articles @ Latest DelveInsight Blogs